Rapport Therapeutics has seen a sharp pullback recently, and that slump puts fresh focus on whether the current share price ...
Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 ...
Tuko News on MSN
Three South Africans reportedly removed from US refugee programme over alleged false claims
Three South Africans reportedly lose places in a US refugee programme over alleged false claims, as a fourth faces scrutiny ...
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results ...
Southern Living on MSN
This South Carolina Bookstore Has A Bar, $1 Popcorn, And A Love Story Behind It
It all started with a chance meeting.
When we played baseball in my high school gym class, I always volunteered to man the outfield. Way, way out in the outfield.
An experimental pill from Boston-based Rapport Therapeutics narrowly succeeded in a mid-stage study focused on bipolar mania, an outcome that analysts described as unexpected and a potential stepping ...
Campus Insights Media on behalf of Pennsylvania State University reports on how parents can help scared children enjoy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results